InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,307.88
(
0.48%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.63
(
0.25%
)
Bitcoin
61,500.15
(
-0.18%
)
Post# of 97239
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

trade2much

Send PM Follow Ignore
Followers 325
Posts 19225
Boards Moderated 1
Alias Born 02/08/2002

trade2much

Re: None

Thursday, 01/30/2014 9:18:24 AM

Thursday, January 30, 2014 9:18:24 AM

Post# of 97239
DNDN PH2 presentation - 8:04AM Dendreon announces presentation of PROVENGE (sipuleucel-T) data at the 2014 Genitourinary Cancer Symposium; data reaffirm positive immune effects of PROVENGE in treatment of advanced prostate cancer; prelim Phase II Data for DN24-02 demonstrate positive immune response in HER2+ urothelial cancer patients (DNDN) 2.79 : Co announced the presentation of four PROVENGE (sipuleucel-T) abstracts and one abstract for DN24-02, an investigational active cellular immunotherapy, from ongoing clinical trials at the 2014 Genitourinary Cancers Symposium (ASCO GU) from January 30-February 1, 2014 in San Francisco, California. The data featuring PROVENGE and DN24-02 studies include:

Watch your thoughts; they become words.
Watch your words; they become actions.
Watch your actions; they become habits.
Watch your habits; they become character.
Watch your character; it becomes your destiny.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up